A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Trial Profile

A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms SERENADE
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 14 Mar 2020 to 28 Mar 2020.
    • 10 Oct 2017 Planned primary completion date changed from 1 Oct 2019 to 28 Mar 2020.
    • 12 Sep 2017 Planned primary completion date changed from 14 Mar 2020 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top